Stifel Financial Corp Sells 41,819 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

Stifel Financial Corp lowered its position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 25.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 122,448 shares of the company’s stock after selling 41,819 shares during the quarter. Stifel Financial Corp owned about 0.07% of X4 Pharmaceuticals worth $82,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Verition Fund Management LLC purchased a new stake in X4 Pharmaceuticals in the third quarter valued at approximately $30,000. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals in the 3rd quarter valued at $37,000. Ensign Peak Advisors Inc grew its holdings in shares of X4 Pharmaceuticals by 4.6% during the 2nd quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after purchasing an additional 111,032 shares during the last quarter. Rhumbline Advisers raised its position in X4 Pharmaceuticals by 14.6% in the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after purchasing an additional 23,831 shares during the period. Finally, K2 Principal Fund L.P. bought a new position in X4 Pharmaceuticals during the 2nd quarter worth approximately $284,000. Institutional investors own 72.03% of the company’s stock.

Analyst Upgrades and Downgrades

XFOR has been the topic of a number of research analyst reports. HC Wainwright reduced their price target on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a report on Thursday, November 14th. Stifel Nicolaus reduced their price target on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

X4 Pharmaceuticals Price Performance

Shares of XFOR opened at $0.81 on Tuesday. The firm’s 50-day simple moving average is $0.52 and its two-hundred day simple moving average is $0.63. X4 Pharmaceuticals, Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $1.60. The stock has a market cap of $137.82 million, a PE ratio of -8.98 and a beta of 0.35. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89.

Insider Buying and Selling

In related news, CEO Paula Ragan sold 239,436 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $131,689.80. Following the transaction, the chief executive officer now directly owns 1,057,713 shares of the company’s stock, valued at approximately $581,742.15. This represents a 18.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Mary Dibiase sold 67,695 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.57, for a total value of $38,586.15. Following the completion of the transaction, the chief operating officer now directly owns 452,060 shares of the company’s stock, valued at approximately $257,674.20. This trade represents a 13.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 580,800 shares of company stock worth $321,447 in the last 90 days. Insiders own 1.62% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.